

2.3: Summary

The following table summarizes important properties for blood anti-coagulant drugs.

Table 2.1: Summary of anti-coagulation agents.

Warfarin		Heparins			DOACS		
		UFH	LWMH	Fondaparinux	Dabigatran	Rivaroxaban	Apixaban
Target	VKORC1 / Indirectly II, X, VI, XI	Anti-thrombin / Indirectly IIa, Xa	Anti-thrombin / Indirectly Xa, IIa (lesser extent)	Anti-thrombin / Indirectly Xa	IIa	Xa	Xa
Type of Molecule	Vitamin K Agonist (coumarin)	Glycosaminoglycan	Glycosaminoglycan	Glycosaminoglycan	Benzamidine	Oxazolidinone	Pyrazolopyridine
Route of Administration	Oral (>99% bioavailability)	IV	IV	IV	Oral	Oral	Oral
Onset	Slow	Fast	Fast	Fast	Fast (1-3 h)	Fast (1-3 h)	Fast (1-3 h)
Duration	Long	Short	Short	Short	Modest	Modest	Modest
Countermeasure	Vitamin K	Protamine Sulfate	Protamine Sulfate	None	Idarucizumab	Andexanet alfa	Andexanet alfa
Other Concerns	Teratogenic	HIT	HIT	No countermeasure	Requires 5-10 days of LMWH priming	Taken with food	

This page titled [2.3: Summary](#) is shared under a [not declared](#) license and was authored, remixed, and/or curated by [Elvin D. de Araujo, Bilal Saqib, Jeffrey W. Keillor, and Patrick T. Gunning](#) (eCampus Ontario) via [source content](#) that was edited to the style and standards of the LibreTexts platform.